These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 24144343)

  • 1. An automated time-of-drug-addition assay to routinely determine the mode of action of HIV-1 inhibitors.
    Van Loock M; Van den Eynde C; Hansen J; Geluykens P; Ivens T; Sauviller S; Bunkens L; Van Acker K; Nijs E; Dams G
    Assay Drug Dev Technol; 2013 Oct; 11(8):489-500. PubMed ID: 24144343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds.
    Jones J; Rodgers J; Heil M; May J; White L; Maddry JA; Fletcher TM; Shaw GM; Hartman JL; Kutsch O
    Assay Drug Dev Technol; 2007 Apr; 5(2):181-89. PubMed ID: 17477827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fluorescence-based high-throughput screening assay to identify HIV-1 inhibitors.
    Geluykens P; Van Acker K; Vingerhoets J; Van den Eynde C; Van Loock M; Dams G
    Methods Mol Biol; 2013; 1030():3-9. PubMed ID: 23821255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel high-throughput cellular screening assay for the discovery of HIV-1 integrase inhibitors.
    Van Loock M; Meersseman G; Van Acker K; Van Den Eynde C; Jochmans D; Van Schoubroeck B; Dams G; Heyndrickx L; Clayton RF
    J Virol Methods; 2012 Feb; 179(2):396-401. PubMed ID: 22172974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput assay to identify inhibitors of Vpu-mediated down-regulation of cell surface BST-2.
    Zhang Q; Liu Z; Mi Z; Li X; Jia P; Zhou J; Yin X; You X; Yu L; Guo F; Ma J; Liang C; Cen S
    Antiviral Res; 2011 Sep; 91(3):321-9. PubMed ID: 21777622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors.
    Blair WS; Isaacson J; Li X; Cao J; Peng Q; Kong GF; Patick AK
    Antiviral Res; 2005 Feb; 65(2):107-16. PubMed ID: 15708637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of triazolothienopyrimidine derivatives as novel HIV-1 replication inhibitors.
    Kim J; Kwon J; Lee D; Jo S; Park DS; Choi J; Park E; Hwang JY; Ko Y; Choi I; Ju MK; Ahn J; Kim J; Han SJ; Kim TH; Cechetto J; Nam J; Ahn S; Sommer P; Liuzzi M; No Z; Lee J
    Bioorg Med Chem Lett; 2013 Jan; 23(1):153-7. PubMed ID: 23206860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific Inhibitors of HIV Capsid Assembly Binding to the C-Terminal Domain of the Capsid Protein: Evaluation of 2-Arylquinazolines as Potential Antiviral Compounds.
    Machara A; Lux V; Kožíšek M; Grantz Šašková K; Štěpánek O; Kotora M; Parkan K; Pávová M; Glass B; Sehr P; Lewis J; Müller B; Kräusslich HG; Konvalinka J
    J Med Chem; 2016 Jan; 59(2):545-58. PubMed ID: 26685880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel and efficient approach to discriminate between pre- and post-transcription HIV inhibitors.
    Daelemans D; Pannecouque C; Pavlakis GN; Tabarrini O; De Clercq E
    Mol Pharmacol; 2005 May; 67(5):1574-80. PubMed ID: 15728798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel Vpr-binding compound that inhibits HIV-1 multiplication in macrophages by chemical array.
    Hagiwara K; Murakami T; Xue G; Shimizu Y; Takeda E; Hashimoto Y; Honda K; Kondoh Y; Osada H; Tsunetsugu-Yokota Y; Aida Y
    Biochem Biophys Res Commun; 2010 Dec; 403(1):40-5. PubMed ID: 21036153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mammalian two-hybrid system-based assay for small-molecular HIV fusion inhibitors targeting gp41.
    Shui X; Lu X; Gao Y; Liu C; Ren F; Jiang Q; Zhang H; Zhao B; Zheng Z
    Antiviral Res; 2011 Apr; 90(1):54-63. PubMed ID: 21352856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput screening using pseudotyped lentiviral particles: a strategy for the identification of HIV-1 inhibitors in a cell-based assay.
    Garcia JM; Gao A; He PL; Choi J; Tang W; Bruzzone R; Schwartz O; Naya H; Nan FJ; Li J; Altmeyer R; Zuo JP
    Antiviral Res; 2009 Mar; 81(3):239-47. PubMed ID: 19118579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1.
    Ellinger B; Pohlmann D; Woens J; Jäkel FM; Reinshagen J; Stocking C; Prassolov VS; Fehse B; Riecken K
    Viruses; 2020 May; 12(5):. PubMed ID: 32466195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Universal modular system for in vitro screening of potential inhibitors of HIV-1 replication].
    Prokof'eva MM; Orlova NN; Gornostaeva AS; Shul'gin AA; Nikitenko NA; Senchenko VN; Lebedev TD; Spirin PV; Riechen K; Fehse B; Stocking C; Prasolov VS
    Mol Biol (Mosk); 2014; 48(2):344-8. PubMed ID: 25850304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1.
    Adelson ME; Pacchia AL; Kaul M; Rando RF; Ron Y; Peltz SW; Dougherty JP
    Antimicrob Agents Chemother; 2003 Feb; 47(2):501-8. PubMed ID: 12543650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of HIV-1 replication?
    Lavigne C; Yelle J; Sauve G; Thierry AR
    AAPS PharmSci; 2002; 4(2):E9. PubMed ID: 12102618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of inhibitors to block interactions of HIV-1 integrase with human LEDGF/p75 via structure-based virtual screening and bioassays.
    Hu G; Li X; Zhang X; Li Y; Ma L; Yang LM; Liu G; Li W; Huang J; Shen X; Hu L; Zheng YT; Tang Y
    J Med Chem; 2012 Nov; 55(22):10108-17. PubMed ID: 23046280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
    Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
    J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing a high-throughput and automated cancer cell proliferation panel for oncology lead optimization.
    Lei M; Ribeiro H; Kolodin G; Gill J; Wang YS; Maloney D; Fan Y; Li S; Myer L; Beluch M; Zhang L; Schweizer L
    J Biomol Screen; 2013 Oct; 18(9):1043-53. PubMed ID: 23733846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reporter gene expression from LTR-circles as tool to identify HIV-1 integrase inhibitors.
    Van Loock M; Hombrouck A; Jacobs T; Winters B; Meersseman G; Van Acker K; Clayton RF; Malcolm BA
    J Virol Methods; 2013 Feb; 187(2):238-47. PubMed ID: 23178583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.